| ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cells O de Barrios, L Sanchez-Moral, M Cortés, C Ninfali, N Profitós-Pelejà, ... Gut 68 (12), 2129-2141, 2019 | 37 | 2019 |
| Immune-checkpoint inhibitors in B-cell lymphoma M Armengol, JC Santos, M Fernández-Serrano, N Profitós-Pelejà, ... Cancers 13 (2), 214, 2021 | 36 | 2021 |
| TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target E Kennedy, E Coulter, E Halliwell, N Profitos-Peleja, E Walsby, B Clark, ... Blood, The Journal of the American Society of Hematology 137 (22), 3064-3078, 2021 | 26 | 2021 |
| Regulation of B-cell receptor signaling and its therapeutic relevance in aggressive B-cell lymphomas N Profitós-Pelejà, JC Santos, A Marín-Niebla, G Roué, ML Ribeiro Cancers 14 (4), 860, 2022 | 24 | 2022 |
| Antitumor activity of the novel BTK inhibitor TG-1701 is associated with disruption of Ikaros signaling in patients with B-cell non–Hodgkin lymphoma ML Ribeiro, D Reyes-Garau, M Vinyoles, N Profitós Pelejà, JC Santos, ... Clinical Cancer Research 27 (23), 6591-6601, 2021 | 11 | 2021 |
| RHOA therapeutic targeting in hematological cancers JC Santos, N Profitós-Pelejà, S Sánchez-Vinces, G Roué Cells 12 (3), 433, 2023 | 8 | 2023 |
| Constitutive activation of p62/Sequestosome-1-mediated proteaphagy regulates proteolysis and impairs cell death in bortezomib-resistant mantle cell lymphoma G Quinet, W Xolalpa, D Reyes-Garau, N Profitós-Pelejà, M Azkargorta, ... Cancers 14 (4), 923, 2022 | 8 | 2022 |
| The ublituximab-umbralisib (U2) drug regimen potentiates the activity of the novel CD47-CD19 bispecific antibody, TG-1801, through the activation of the G protein-coupled … E Normant, ML Ribeiro, N Profitos-Peleja, P Blecua, D Reyes-Garau, ... Blood 138, 1196, 2021 | 8 | 2021 |
| Antitumor Activity of Simvastatin in Preclinical Models of Mantle Cell Lymphoma JC Santos, N Profitós-Pelejà, ML Ribeiro, G Roué Cancers 14 (22), 5601, 2022 | 3 | 2022 |
| Prolonged cell cycle arrest by the CDK4/6 antagonist narazaciclib restores ibrutinib response in preclinical models of BTKi‐resistant mantle cell lymphoma. N Profitós‐Pelejà, ML Ribeiro, J Parra, M Fernández‐Serrano, ... Hematological Oncology 41, 2023 | 2 | 2023 |
| G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy ML Ribeiro, N Profitós-Pelejà, JC Santos, P Blecua, D Reyes-Garau, ... Frontiers in immunology 14, 1130052, 2023 | 2 | 2023 |
| Exportin 1‐mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma M Caillot, H Miloudi, A Taly, N Profitós‐Pelejà, JC Santos, ML Ribeiro, ... Molecular Oncology 17 (12), 2546-2564, 2023 | 1 | 2023 |
| Narazaciclib, a Differentiated CDK4/6 Antagonist, Prolongs Cell Cycle Arrest and Metabolomic Reprogramming, Enabling Restoration of Ibrutinib Sensitivity in Btki-Resistant … N Profitos-Peleja, ML Ribeiro, J Parra, M Fernandez-Serrano, ... Blood 142, 4181, 2023 | 1 | 2023 |
| Safety and efficacy of EZH2 and BRD4 dual targeting in EZH2Y641mut germinal centre-derived lymphoma A Chamorro-Jorganes, ML Ribeiro, N Profitos-Peleja, D Reyes-Garau, ... Cancer Research 80 (16_Supplement), 2925-2925, 2020 | 1 | 2020 |
| Synergistic activity of the CDK4/6 antagonist narazaciclib (ON123300) with irreversible BTK inhibition in ibrutinib-resistant mantle cell lymphoma N Profitos-Peleja, ML Ribeiro, AM Silverstein, S Cosenza, G Roué Cancer Research 83 (7_Supplement), 5974-5974, 2023 | | 2023 |
| Design and functional characterization of a first-in-class irreversible inhibitor of HOIL-1-interacting protein (HOIP) with selective antitumor activity against B-cell non … AM Montagut, MAA Cubillos, G Gorjón-de-Pablo, J Farrés, LH Garcia, ... Cancer Research 83 (7_Supplement), 4980-4980, 2023 | | 2023 |
| GPR183 mediates the capacity of the novel CD47-CD19 bispecific antibody TG-1801 to heighten ublituximab-umbralisib (U2) anti-lymphoma activity ML Ribeiro, N Profitós-Pelejà, JC Santos, P Blecua, DR Garau, ... bioRxiv, 2022.03. 31.486558, 2022 | | 2022 |
